Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of various medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company is developing its lead antibody product candidate, SRK-015, a first-in-class inhibitor of the activation of myostatin that is in clinical development stage for the treatment of spinal muscular atrophy. It is also developing various product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. Scholar Rock Holding Corporation has a strategic collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. The company was founded in 2012 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone857-259-3860
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$370,000.00
Profitability
Miscellaneous
Employees50
OptionableNot Optionable
Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions
What is Scholar Rock's stock symbol?
Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."
What price target have analysts set for SRRK?
4 equities research analysts have issued twelve-month price targets for Scholar Rock's shares. Their predictions range from $25.00 to $31.00. On average, they expect Scholar Rock's stock price to reach $27.3333 in the next twelve months. This suggests a possible upside of 51.9% from the stock's current price. View Analyst Price Targets for Scholar Rock.
What is the consensus analysts' recommendation for Scholar Rock?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scholar Rock.
Has Scholar Rock been receiving favorable news coverage?
Media headlines about SRRK stock have been trending somewhat negative on Wednesday, InfoTrie reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Scholar Rock earned a news impact score of -1.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Scholar Rock's key competitors?
Some companies that are related to Scholar Rock include Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Alector (ALEC), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Iovance Biotherapeutics (IOVA), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT), Fate Therapeutics (FATE), Coherus Biosciences (CHRS) and Sangamo Therapeutics (SGMO).
Who are Scholar Rock's key executives?
Scholar Rock's management team includes the folowing people:
- Mr. Nagesh K. Mahanthappa Ph.D., Pres, CEO & Exec. Director (Age 54)
- Mr. Yung H. Chyung, Chief Medical Officer (Age 43)
- Ms. Rhonda M. Chicko, Chief Financial Officer (Age 53)
- Mr. Alan J. Buckler, Chief Scientific Officer (Age 59)
- Junlin Ho, VP & Head of Corp. Legal
When did Scholar Rock IPO?
(SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Scholar Rock's major shareholders?
Scholar Rock's stock is owned by a number of of institutional and retail investors. Top institutional investors include Artal Group S.A. (9.10%), BB Biotech AG (5.07%), BlackRock Inc. (1.47%), Sphera Funds Management LTD. (0.70%), Geode Capital Management LLC (0.32%) and Northern Trust Corp (0.28%). Company insiders that own Scholar Rock stock include Amir Nashat and International SCA Artal. View Institutional Ownership Trends for Scholar Rock.
Which major investors are selling Scholar Rock stock?
SRRK stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Artal Group S.A., Victory Capital Management Inc. and TD Asset Management Inc.. View Insider Buying and Selling for Scholar Rock.
Which major investors are buying Scholar Rock stock?
SRRK stock was purchased by a variety of institutional investors in the last quarter, including BB Biotech AG, Millennium Management LLC, Geode Capital Management LLC, New York State Common Retirement Fund, Bank of New York Mellon Corp, Northern Trust Corp and BlackRock Inc.. Company insiders that have bought Scholar Rock stock in the last two years include Amir Nashat and International SCA Artal. View Insider Buying and Selling for Scholar Rock.
How do I buy shares of Scholar Rock?
Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Scholar Rock's stock price today?
One share of SRRK stock can currently be purchased for approximately $18.00.
How big of a company is Scholar Rock?
Scholar Rock has a market capitalization of $454.32 million and generates $370,000.00 in revenue each year. Scholar Rock employs 50 workers across the globe.
What is Scholar Rock's official website?
How can I contact Scholar Rock?
Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected]
MarketBeat Community Rating for Scholar Rock (NASDAQ SRRK)
MarketBeat's community ratings are surveys of what our community members think about Scholar Rock and other stocks. Vote "Outperform" if you believe SRRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
